Search the Newsreel

Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ)

Monopar Therapeutics Inc. (MNPR) was downgraded to Neutral from Overweight by Cantor Fitzgerald after a significant rally in its stock price. Cantor Fitzgerald believes the clinical-stage biopharma is now fairly valued following a nearly 90% increase over the past six months. This downgrade led …

Monopar Therapeutics Releases Q2 2026 Financial Results

Monopar Therapeutics Inc. reported a widening net loss of $5.3M, or $0.62 per share, for Q2 2026, compared to a loss of $0.35 per share in the prior year. This increase in losses is attributed to the capital-intensive nature of advancing its cancer treatment …

Saturn V Capital shows sub-5% Monopar Therapeutics (MNPR) stake in 13G/A

Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Monopar Therapeutics (NASDAQ:MNPR) reported a quarterly EPS of ($0.79), missing analysts' consensus estimate of ($0.66) by $0.13. Despite the earnings miss, the stock is trading near its 52-week high, and analysts maintain a "Buy" rating with a consensus price target of $112.08. Institutional investors …

Adage Capital discloses 4.76% Monopar Therapeutics (MNPR) stake including warrants

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 4.76% in Monopar Therapeutics Inc. (MNPR). This stake includes 324,195 shares of common stock, with 115,000 shares being issuable upon the exercise of warrants. The ownership represents …

Monopar Q2 Net Loss Widens; Rolling NDA Submission For ALXN1840 In Wilson Disease Underway

(RTTNews) - Monopar Therapeutics Inc. (MNPR), a clinical-stage biopharmaceutical company, reported financial results for the second quarter of 2026, reflecting a wider net loss, and provided an update on its investigational pipeline. Monopar Therapeutics' lead investigational candidate ALXN1840 (tiomolibdate choline, TMC) is in development …

Monopar Therapeutics reports Q2 2026: $5.3M net loss, $134.3M cash on hand

Monopar Therapeutics reported a net loss of $5.3 million for Q2 2026 and held $134.3 million in cash, cash equivalents, and investments. The company expects these funds to support operations through at least December 31, 2027, as it advances an NDA rolling submission for …

Monopar Therapeutics (MNPR) deepens R&D spend but retains $134M cash runway

Monopar Therapeutics (MNPR) reported a net loss of $9.21 million for the first half of 2026, an increase from $5.08 million a year prior, primarily due to higher research and development (R&D) spending on its ALXN1840 Wilson disease program and radiopharmaceutical pipeline. Despite the …

Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPR) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, though the broader analyst consensus remains a "Buy" with an average price target of $112.08. The company recently reported better-than-expected quarterly EPS of negative $0.46 and has …

Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview

Monopar Therapeutics Inc. is projected to report a loss of 62 cents per share, according to this earnings preview. The article indicates that this information comes from Reuters via Refinitiv and is accessible through TradingView's news platform.

Monopar Therapeutics stock approaches $125.77 resistance as bullish momentum drives gains

Monopar Therapeutics (MNPR) Projected to Post Earnings on Tuesday

Monopar Therapeutics (NASDAQ:MNPR) Reaches New 52-Week High - What's Next?

Monopar Therapeutics (MNPR) Slips Slightly as Biotech Sector Faces Profit-Taking - Iceberg Order

Monopar Therapeutics Inc (MNPR) Institutional Confidence

Monopar Therapeutics Inc (MNPR) has an institutional shareholding score of 7.00, placing it 80th out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 88.03%, marking a 29.07% increase quarter-over-quarter. Janus Henderson Investors, RA Capital Management, LP, and Adage …

Monopar Therapeutics Inc (MNPR) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a detailed historical overview of Monopar Therapeutics Inc (MNPR) dividends and stock splits. It indicates that no dividends have been distributed by the company over the past five years and lists multiple upcoming stock splits of type "Merger" with a 5-to-1 …

Monopar Therapeutics Inc (MNPR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Monopar Therapeutics Inc (MNPR), listing its major shareholders and institutional holdings. Key institutional investors include Janus Henderson Investors, RA Capital Management, L.P., and Adage Capital Management, L.P., alongside an overview of institutional shareholding trends over recent quarters. …

Monopar Therapeutics Inc (MNPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey reports on Monopar Therapeutics Inc (MNPR)'s revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The article also provides the current stock trading information for MNPR.

Monopar Therapeutics Inc (MNPR) Cash Flow

This article provides the quarterly and annual cash flow statements and related financial data for Monopar Therapeutics Inc (MNPR). It details operating, investing, and financing cash flows, along with changes in net income, working capital, and cash balances over various fiscal quarters from 2017 …

MONOPAR THERAPEUTICS INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $125 FROM $105

H.C. Wainwright has raised its target price for MONOPAR THERAPEUTICS INC. to $125 from the previous $105. This news was reported by Reuters. The article is very short, focusing solely on this price update.

H.C. Wainwright raises Monopar stock price target to $125 on NDA filing

H.C. Wainwright has increased its price target for Monopar Therapeutics (NASDAQ:MNPR) to $125 from $105, maintaining a Buy rating, following Monopar's initiation of a rolling NDA submission for ALXN1840 for Wilson disease. The stock has seen a significant 140% increase over the past year. …

Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 8.9% - What's Next?

Monopar Therapeutics (MNPR) Proxy Filing Summary

Monopar Therapeutics has released a proxy filing summary detailing an Annual Meeting scheduled for August 5, 2024. Stockholders will vote on four proposals: election of six directors, ratification of BPM LLP as auditor, approval of a reverse stock split, and an amendment to the …

Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease

Monopar Therapeutics has initiated a rolling application for ALXN1840, a drug designed to treat Wilson disease, in collaboration with Alexion. This marks a significant step towards regulatory approval for patients suffering from this rare genetic disorder. The application process will allow for continuous submission …

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

Monopar Therapeutics Inc. has begun a rolling New Drug Application (NDA) submission to the U.S. FDA for ALXN1840 (tiomolibdate choline, TMC) to treat Wilson disease. This first-in-class therapy, which has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations, would be the first …

Can leadership appointments spark further gains for Monopar Therapeutics stock?

MNPR stock draws attention as Monopar Therapeutics advances pipeline and reports recent financing metrics

Monopar Therapeutics (MNPR) is a clinical-stage biotech focused on cancer treatments, with its stock valuation tied to pipeline progress and financing. The company reported increased operating expenses and a net loss in 2025 due to expanded research, funded by equity offerings. Investors are closely …

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

Monopar Therapeutics Inc. has enhanced its commercial leadership team by appointing Nicole Sweeny to its Board of Directors and hiring Sharon Funk and Daniel Olmstead for key commercial roles. These strategic additions aim to support the anticipated launch of ALXN1840, Monopar's first commercial product …

Former KalVista chief joins Monopar board as Wilson drug prep expands

Monopar (Nasdaq: MNPR) announced key commercial leadership additions to support the anticipated launch of its first potential commercial product, ALXN1840, for Wilson disease. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, was elected to the Board of Directors, while Sharon Funk and Daniel …

MNPR stock trades quietly as Monopar Therapeutics advances cancer pipeline

Monopar Therapeutics (MNPR) is a clinical-stage oncology company that reported no revenue and a net loss of $10.9 million in 2023, relying on external funding for its pipeline. The company is advancing Validive for oral mucositis and camsirubicin for soft tissue sarcoma, with its …

Cantor Fitzgerald reiterates Monopar stock Overweight rating at $109 By Investing.com

Cantor Fitzgerald has reiterated an Overweight rating and a $109 price target for Monopar Therapeutics (NASDAQ:MNPR), ahead of an expected New Drug Application submission for ALXN1840 for Wilson disease. The firm highlighted Monopar's significant stock return and upward earnings revisions, while also addressing investor …